Josep V. Forment

An inducible BRCA1 expression system with in vivo applicability uncovers activity of the combination of ATR and PARP inhibitors to overcome therapy resistance

This paper develops an inducible BRCA1 expression system to study hypomorphic variants and finds that combining ATR and PARP inhibitors overcomes resistance caused by BRCA1 {Delta}exon11 hypomorphs.

Androgen receptor inhibition extends PARP inhibitor activity in prostate cancer models beyond BRCA mutations and defects in homologous recombination repair.

This study shows that combining androgen receptor inhibitors with PARP inhibitors enhances DNA damage in prostate cancer models, independent of BRCA mutations, by increasing double-strand breaks and micronuclei formation.

High levels of DNA replication initiation factors indicate ATR inhibitor sensitivity via excessive origin firing

This study identifies that high levels of DNA replication initiation factors correlate with ATR inhibitor sensitivity due to excessive origin firing in cancer cells.

Simultaneous inhibition of DNA-PK and Pol{Theta} improves integration efficiency and precision of genome editing

This study identifies AZD7648 and Pol{Theta} inhibitors as a combination (2iHDR) that enhances CRISPR-Cas9 integration efficiency and precision by targeting DNA-PK and MMEJ repair pathways.

Detection of functional protein domains by unbiased genome-wide forward genetic screening

This paper describes a method to detect functional protein domains by identifying suppressor mutations in yeast and mouse cells, revealing insights into protein function and drug resistance mechanisms.